Latvia Pharmaceuticals and Healthcare Report Q4 2014

  • August 2014
  • -
  • Business Monitor International
  • -
  • 107 pages

Includes 3 FREE quarterly updates

BMI View:
Latvia's macroeconomic environment continues to improve at the same time as smooth transitions to a new currency and new Prime Minister. Market growth forecasts are strong although the country will continue to present a modest opportunity to larger multinational companies on account of its relatively small market size. Meanwhile, tensions between Ukraine and Russia may provide challenges for local manufacturers looking towards exports to Russia to boost revenue.

Headline Expenditure Projections
- Pharmaceuticals: EUR325mn (USD429mn) in 2013 to EUR341mn (USD458mn) in 2014; +5.0% in local currency terms and +6.6% in US dollar terms.
- Healthcare: EUR0.94bn (USD1.24bn) in 2013 to EUR0.98bn (USD1.32bn) in 2014; +4.5% in local currency terms and +6.1% in US dollar terms.

Table Of Contents

Latvia Pharmaceuticals and Healthcare Report Q4 2014
BMI Industry View 7
SWOT 9
Political . 11
Economic 12
Business Environment .. 13
Industry Forecast .. 14
Pharmaceutical Market Forecast 14
Table: Pharmaceutical Sales, Historical Data And Forecasts (Latvia 2010-2018).15
Healthcare Market Forecast .. 16
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Latvia 2010-2018). 17
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Latvia 2010-2018).. . 17
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Latvia 2010-2018). . 18
Prescription Drug Market Forecast 18
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Latvia 2010-2018).. 19
Patented Drug Market Forecast . 20
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Latvia 2010-2018) . 21
Generic Drug Market Forecast .. 21
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Latvia 2010-2018)22
Latvia 23
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Latvia 2010-2018).. 24
Pharmaceutical Trade Forecast . 24
Table: Pharmaceutical Trade Data And Forecasts (Latvia 2012-2018).. . 25
Table: Pharmaceutical Trade Data And Forecasts local currency (Latvia 2012-2018) 25
Other Healthcare Data . 26
Table: Physicians By Specialty, 2004-2010 26
Key Risks To BMI's Forecast Scenario . 27
Macroeconomic Forecasts 29
Economic Analysis 29
Real GDP By Expenditure Breakdown 31
Risks To Outlook 35
Table: Economic Activity (Latvia 2009-2018).. . 35
Industry Risk Reward Ratings .. 36
Central And Eastern Europe Risk/Reward Ratings . 36
Latvia Risk/Reward Ratings 43
Rewards 43
Risks 43
Market Overview 45
Industry Trends And Developments 47
Epidemiology 47
Table: Leading Causes of Death, 1990-2010..47
Table: New Cases of Cancer, 2004-2010. 49
Table: Cumulative Reported Cases of HIV and AIDS, 2000-2010. . 50
Healthcare Sector .. 51
Healthcare Sector Funding .. 51
Healthcare Provision .. 53
Table: Hospitals and Beds, 2006-2010.. . 54
Table: Hospital Beds by Specialty, 2004-2010.. 54
Research and Development 55
Biotechnology 56
Clinical Trials 58
Regulatory Development .. 59
Regional Collaboration 60
Intellectual Property Developments 61
Pricing Regime .. 62
Reimbursement Regime 64
Competitive Landscape 66
Pharmaceutical Industry . 66
Table: Licences Issued To Companies Engaged In Pharmaceutical Manufacturing And Distribution, 2007-2011..66
Table: Medicines Consumption According To Marketing Authorisation Holders (turnover in LVL).67
Pharmaceutical Industry Developments .. 68
Pharmaceutical Wholesale 69
Table: Wholesale Mark-Up Scheme For Reimbursable Pharmaceuticals, 2008..70
Table: Wholesalers Market Share, 2010 (%)..71
Pharmaceutical Retail . 72
Table: Pharmacy Mark-Up Scheme For Reimbursable Pharmaceuticals, 2008..72
Table: Licences Issued To Pharmacies.74
Company Profile 76
Grindeks 76
Olainfarm .. 82
Pfizer 86
GlaxoSmithKline . 88
Sanofi 91
Novartis . 93
Merck and Co 95
Demographic Forecast . 97
Table: Latvia's Population By Age Group, 1990-2020 ('000) 98
Table: Latvia's Population By Age Group, 1990-2020 (% of total). 99
Table: Latvia's Key Population Ratios, 1990-2020 100
Table: Latvia's Rural And Urban Population, 1990-2020. 100
Glossary 101
Methodology 103
Pharmaceutical Expenditure Forecast Model 103
Healthcare Expenditure Forecast Model 103
Notes On Methodology .. 104
Risk/Reward Ratings Methodology .. 105
Ratings Overview . 106
Table: Pharmaceutical Risk/Reward Ratings Indicators. . 106
Indicator Weightings 107

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Louis

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers

PharmaPoint: Irritable Bowel Syndrome - Global Drug Forecast and Market Analysis to 2023

PharmaPoint: Irritable Bowel Syndrome - Global Drug Forecast and Market Analysis to 2023

  • $ 10 995
  • Industry report
  • December 2014
  • by Global Data

PharmaPoint: Irritable Bowel Syndrome - Global Drug Forecast and Market Analysis to 2023 Summary Irritable Bowel Syndrome (IBS) is a common disorder characterized by abdominal discomfort associated with ...

OpportunityAnalyzer: Cushing’s Syndrome - Opportunity Analysis and Forecasts to 2018

OpportunityAnalyzer: Cushing’s Syndrome - Opportunity Analysis and Forecasts to 2018

  • $ 7 995
  • Industry report
  • January 2015
  • by Global Data

OpportunityAnalyzer: Cushing’s Syndrome - Opportunity Analysis and Forecasts to 2018 Summary GlobalData estimates that the 2013 sales for the Cushing’s syndrome (CS) therapeutic market was approximately ...

PharmaPoint: Irritable Bowel Syndrome - 5EU Drug Forecast and Market Analysis to 2023

PharmaPoint: Irritable Bowel Syndrome - 5EU Drug Forecast and Market Analysis to 2023

  • $ 6 995
  • Industry report
  • December 2014
  • by Global Data

PharmaPoint: Irritable Bowel Syndrome - 5EU Drug Forecast and Market Analysis to 2023 Summary Irritable Bowel Syndrome (IBS) is a common disorder characterized by abdominal discomfort associated with altered ...


Download Unlimited Documents from Trusted Public Sources

Cancer Drug Market in Mexico

  • April 2015
    2 pages
  • Cancer Drug  

    Public Health I...  

    Pharmaceutical  

  • Mexico  

    Brazil  

    North America  

View report >

Opioid Industry in the US

  • April 2015
    13 pages
  • Opioid  

  • United States  

View report >

Drug And Medication Industry in the US

  • April 2015
    2 pages
  • United States  

View report >

Opioid Market

5 days ago

Related Market Segments :

Pharmaceutical
Medicine

ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.